We previously tested the efficacy of Plk1 inhibition in NSCLC cell lines with acquired resistance to EGFR inhibitors and found that cell lines that had undergone EMT, but not those with T790M mutations, became more sensitive to Plk1 inhibition (Wang et al, 2016). This evidence concerns the gene PLK1 and non-small cell lung carcinoma.